Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Posts Tagged ‘medicine’

41st International Engineering in Medicine and Biology Conference

Posted by fidest press agency su mercoledì, 24 luglio 2019

Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology (EMB) Conference, July 23 through July 27, in Berlin. The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference.
The conference, hosted by the IEEE Engineering in Medicine and Biology Society (EMBS) will focus on the theme, “Biomedical engineering ranging from wellness to intensive care.” During an innovative and interactive special session on Tumor Treating Fields, a neurosurgeon, a radiologist, two biomedical engineers who have worked on novel solutions to treat brain cancer, and a glioblastoma patient will discuss the treatment process, evaluating candidate therapeutic technologies. The oral presentations will describe studies utilizing numerical simulations to better understand Tumor Treating Fields distribution within the body and how Tumor Treating Fields interact with cells. These studies are setting the foundation for optimizing Tumor Treating Fields dosimetry in treatment planning. “The EMB Conference showcases the latest technologies, innovations and applications to human health and well-being and provides a roadmap for the future,” said Dr. Uri Weinberg, Novocure’s Vice President of Clinical Development. “We are pleased that the focus on Tumor Treating Fields continues to expand at this conference. We look forward to participating in this important scientific exchange and exposing the biomedical engineering community to the science of Tumor Treating Fields therapy.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

BioGENEius Challenge Announces 2019 BioGENEius Hall of Fame Awardee

Posted by fidest press agency su martedì, 4 giugno 2019

The Biotechnology Institute announced the winner of the BioGENEius Hall of Fame Award, who will be recognized next week at the 2019 BIO International Convention in Philadelphia. Each year, the Biotechnology Institute honors a past BioGENEius who best exemplifies the goals of its mission. This year we honor Michael Duong, a medical student and science advocate at the Perelman School of Medicine at the University of Pennsylvania.
Duong’s interest in science began in his childhood, creating his own “basement laboratory” complete with incubators and centrifuges. He accelerated his scientific explorations in high school with a student internship at Kibow Biotech. His passion for science led him to years of independent research and science fairs, culminating in the 2014 and 2015 International BioGENEius Challenge, the 2017 Goldwater Scholarship in Life Sciences and the 2019 Marc S. Levine Radiology Research Prize. Duong has also received honors from the US Surgeon General, House of Representatives, Department of Education and Department of Agriculture, as well as National Merit/AP scholarships.Duong’s aim is to become a physician, scientist and educator at the forefront of improving diagnosis and management of Alzheimer’s Disease.His current research focuses on applying machine learning and artificial intelligence to improve diagnosis of brain diseases and harnessing non-invasive neuroimaging biomarkers to demystify dementia progression. Michael hopes to streamline diagnosis and provide a platform for healthcare providers and the biotech industry to improve communication and discovery.As a Vietnamese American, son of refugees and family caregiver, Duong is shaped by ancestral, cultural and religious heritage. From listening to the story of his mother’s harrowing trip across the South China Sea on a wooden boat, he learned gratitude and perseverance. From caring for his grandfather with dementia, he learned compassion and patience. Duong applies these lessons of humanity and peace to his approach to molecular and computational neuroscience. By investigating Alzheimer’s disease progression in different populations, he hopes to develop tools and treatments to empower personalized care for patients. As dementia prevalence is rising substantially in developing nations like Vietnam, Michael realizes that biomedical science must be diverse and provide precision management and treatments that are unique for each population and person. Leveraging heritage and life lessons, Michael embraces the love of – and duty to – his ancestors to help cognitively impaired patients and their families.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

87th European Atherosclerosis Society Congress

Posted by fidest press agency su mercoledì, 29 maggio 2019

The Medicines Company (NASDAQ: MDCO) today announced presentation of analyses of two clinical studies of inclisiran at the 87th European Atherosclerosis Society (EAS) Congress in Maastricht, Netherlands. A combined analysis (N=279) from the Phase 2 ORION-1 and Phase 1 ORION-7 trials, presented during an e-poster session, demonstrated that patients across a range of renal function levels achieved consistent reductions in low-density lipoprotein cholesterol (LDL-C) with no dose adjustment necessary for patients with renal impairment. Results from the Phase 2 ORION-2 pilot study, presented as a late-breaking abstract, showed that inclisiran provided durable reductions in LDL-C levels up to day 180 in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high levels of LDL-C and early onset of cardiovascular disease, without the need to increase the dose of inclisiran.“The information discussed at EAS supports inclisiran’s potential to address the high burden of cardiovascular disease caused by cumulative exposure to elevated LDL-C,” said Peter Wijngaard, Ph.D., Chief Development Officer of The Medicines Company. “We are pleased with these findings that demonstrate inclisiran’s potent, durable and consistent lowering of LDL-C, as well as favorable tolerability and safety, in patients with renal insufficiency or HoFH.”Inclisiran, the first cholesterol-lowering therapy in the siRNA class, is The Medicines Company’s investigational therapy in Phase 3 clinical development to evaluate its ability to lower LDL-C through twice-a-year dosing. The company expects pivotal Phase 3 data readouts for inclisiran in the third quarter of 2019 followed by anticipated regulatory filings in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.“There remains significant unmet need in the treatment of ASCVD, as approximately four out of five statin-treated patients are not at LDL-C goals, with poor adherence to therapy a major underlying cause,” said Mark Timney, Chief Executive Officer of The Medicines Company. “We are excited at the prospect of bringing forward a revolutionary approach to treat cardiovascular disease using a twice-a-year therapy with unique potential to address the need for additional LDL-C lowering and long-standing medication adherence challenges faced by millions of people.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Ross University School of Medicine (RUSM) today celebrated its ceremony at the Watsco Center

Posted by fidest press agency su lunedì, 20 maggio 2019

Coral Gables, FloridaVivian W. Pinn, M.D., was the keynote speaker. She was the inaugural full-time director of the Office of Research on Women’s Health at the National Institutes of Health (NIH) beginning in 1991 and associate director of NIH for Women’s Health Research from 1994 until her retirement in 2011.“We are honored to have such a distinguished physician, scientist and researcher as our commencement speaker,” said William F. Owen, Jr., M.D., FACP, dean and chancellor of RUSM. “Over the course of her long career, Dr. Pinn has consistently led the advancement of women’s health research, as well as developed career pathways and opportunities for women in medicine and science. Her own journey through the segregated schools of Lynchburg, Virginia, to earning her M.D. as the only woman and minority in her class at the University of Virginia School of Medicine, to becoming a world-renowned biomedical researcher is truly inspirational. She is an example to our graduates about the many opportunities that lie ahead.”Dr. Pinn led the implementation of NIH’s research inclusion policies and developed the national strategic plan for women’s health research. She established many new research funding initiatives and career development programs in collaboration with the NIH Institutes and Centers. During that time, she also established the NIH Committee on Women in Biomedical Careers with the NIH Director. Following her retirement, Dr. Pinn was named as a senior scientist emerita at the NIH Fogarty International Center.“I welcomed the opportunity to be the keynote speaker for Ross University School of Medicine, and to address this diverse group of future physician leaders,” said Dr. Pinn. “RUSM has a strong record of quality academics and over 14,000 alumni who serve their patients and communities with passion and commitment.” Dr. Pinn has held leadership positions in many professional organizations, including as the 88th president of the National Medical Association (NMA) and is currently chair of the NMA Past Presidents Council. She serves on the Board of Trustees/Advisors of Thomas Jefferson University, the Sidney Kimmel Cancer Center at Jefferson, and Tufts University School of Medicine. She is also a fellow of the American Academy of Arts and Sciences and was elected to the National Academy of Medicine in 1995.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Modernizing Medicine Gastroenterology

Posted by fidest press agency su sabato, 18 maggio 2019

Specialty-specific healthcare information technology leader Modernizing Medicine® Gastroenterology, formerly gMed®, announced a bi-directional clinical lab connection within the company’s gastro-specific suite of solutions, gGastro®, through its collaboration with Change Healthcare. During the annual Digestive Disease Week® (DDW) taking place in San Diego, Calif., from May 18 – 21, 2019, the new capability will be highlighted at Modernizing Medicine Gastroenterology’s booth #1142.Change Healthcare’s Exchange Orders and Results solution allows physicians to electronically submit clinical lab orders from within gGastro, as well as receive the results directly from connected labs. The streamlined workflow provides Modernizing Medicine customers with a more efficient way to communicate with laboratories, hospitals, and physician practices, and helps providers to seamlessly process and bill orders.
The company will also showcase its enhanced gGastro® Mobile EHR app solution. Compatible with iOS and Android, gGastro Mobile allows providers to access schedules, view upcoming procedures, review medication history, patient data and more right from their smartphone. The new tasking feature gives providers access to easily reply, view and complete tasks from the convenience of their phone, and they can now sign into the app with biometric verification.”Our physicians have greatly benefited from the convenience and flexibility that gGastro Mobile offers. One of our physicians was working from home when his internet went out. By using the mobile EHR, he was able to easily access his patients’ records via the app and avoided the 30-minute drive back to the office,” shared Tasha Cieslak*, practice manager at The Gastro Clinic.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

The curative use of stem cells in regenerative medicine

Posted by fidest press agency su venerdì, 10 maggio 2019

Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the journal Nature published data demonstrating improvements in the production of beta cells (cells that produce insulin) from stem cells. Led by Harvard University researchers in collaboration with scientists from Semma, the study characterized the types of cells produced by the applicable cell differentiation methods, and demonstrated biological and physical separation methods to increase the purity of beta cells in a sample of converted stem cells from 30 to 80 percent.“The implications of these findings could be tremendously important in developing effective therapies for the more than 1.25 million people living with Type 1 diabetes in the U.S.,” said Bastiano Sanna, Ph.D., Chief Executive Officer of Semma Therapeutics. “We are immensely grateful to our collaborators at Harvard University, including Prof. Doug Melton, whose lab showed for the first time in 2014 that stem cells could be converted to functional beta cells, and who led the research presented in this important manuscript. These findings provide a solid foundation to continue to advance Semma’s mission to develop and provide best-in-class islet cell therapies for patients.”Published results summarize the single-cell sequencing and molecular biology used to identify genes expressed by each cell and the classification of those cells based on expression patterns. The paper also details the discovery of a protein expressed uniquely by beta cells, which was used to “fish” beta cells from the mixture, as well as a physical enrichment method developed by Semma scientists, which together were able to improve the purity of beta cells by more than two-fold.The manuscript, titled “Charting cellular identity during human in vitro β-cell differentiation,” may be found here. A press release issued by Harvard University describes the scientific findings in brief.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Announces Latest Institute for Value-Based Medicine® Meeting

Posted by fidest press agency su sabato, 23 marzo 2019

The American Journal of Managed Care® (AJMC®), the leading peer-reviewed journal dedicated to issues in managed care, will host a regional Institute for Value-Based Medicine® meeting on advances in treatment and management to reduce the costs and improve the outcomes of patients with diabetes. The meeting will take place Wednesday, April 17, 6-9 p.m., at Loews Santa Monica Beach Hotel in California and will be chaired and moderated by Peter C. Butler, M.D., professor of medicine, endocrinology, diabetes and hypertension, David Geffen School of Medicine, and director of the Larry L. Hillblom Islet Research Center at the University of California, Los Angeles (UCLA).“We look forward to presenting our latest meeting on diabetes treatment and management,” said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of AJMC®. “Attendees who participate in this live educational program will gain expert insight into best practices in diabetes value-based care from leading health systems, receive practical guidance on implementation of patient-centric care and will learn about innovative models for diabetes treatment and management.”

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Samsung Bioepis’ First Oncology Medicine in the United States

Posted by fidest press agency su mercoledì, 23 gennaio 2019

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1 (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. Please see Boxed Warnings and Important Safety Information for ONTRUZANT® below.
ONTRUZANT® is Samsung Bioepis’ first oncology biosimilar to receive FDA approval, and will be marketed and distributed in the United States (US) by Merck, which is known as MSD outside of the US and Canada.“For many cancer patients in the US, battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment. Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We sincerely hope our trastuzumab biosimilar will do exactly that,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening the availability of approved treatments for cancer patients across the US.” ONTRUZANT® was also approved by the European Commission (EC) in November 2017, and has since been launched in a growing number of European countries.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

Posted by fidest press agency su mercoledì, 23 gennaio 2019

At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the “Group” refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) As part of its mission to introduce new therapeutic drugs for the central nervous system, the Group is moving forward with the development of programs for chronic motor deficit from traumatic brain injury (TBI) and chronic motor deficit from ischemic stroke, centering on the United States and Japan. Regarding the program for treatment of chronic motor deficit from TBI, positive results were announced on November 1, 2018, with respect to a Phase 2 clinical trial, namely that “Patients administered SB623 demonstrated a statistically significant improvement in their motor function compared to the control group, confirming that the study has met its primary endpoint.” Regarding the program targeting chronic motor deficit from ischemic stroke, the Company expects to announce results of a Phase 2b clinical trial in the first half of the fiscal year ending January 31, 2020 (from February 1, 2019 to July 31, 2019).Given the positive results of the program targeting chronic motor deficit from TBI mentioned above, the Group has reevaluated the scope of indications for SB623. Consequently, the Company has decided to initiate a program for treatment of chronic motor deficit from cerebral hemorrhage, which is similar to TBI, as a new indication for SB623. The Company is considering Japan and the United States as development regions for this program.
Ischemic stroke is caused by the blockage of blood vessels, whereas cerebral hemorrhage results from ruptured blood vessels. Both can result in hemiplegia, sensory impairment, or memory impairment. Currently, no definitive therapy exists.As of today, the Company expects to commence clinical trials for this program from Phase 2 or Phase 3. However, the development details and timing are not yet decided. The Company will provide these as soon as they become available.
This decision does not affect the Company’s consolidated operating performance for the fiscal year ending January 31, 2019.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

2° Congresso internazionale della European Alliance for Personalised Medicine

Posted by fidest press agency su venerdì, 16 novembre 2018

Milano mercoledi 28 novembre ore 13.00 Sala 39 (Piano 39°), Palazzo Regione Lombardia,
Piazza Città di Lombardia 1, 2° Congresso internazionale della European Alliance for Personalised Medicine. Alla presentazione del progetto Europeo “Regions4Permed” saranno presenti rappresentanti della Commissione Europea, della EAPM e delle realtà italiane coinvolte: Toscana Life Sciences per la Regione Toscana e Fondazione Regionale per la Ricerca Biomedica per la Regione Lombardia.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Adtalem Global Education Announces Barbados as New Location for Ross University School of Medicine

Posted by fidest press agency su lunedì, 6 agosto 2018

Adtalem Global Education (NYSE: ATGE), a leading global education provider, today announced it is relocating Ross University School of Medicine (RUSM)’s medical sciences campus to Barbados. The academic center will be in Bridgetown, leveraging existing facilities centrally located in the vibrant capital city. Student housing will be located in the parish of Christ Church at an existing housing community that includes access to a community center, shopping, day care, student services and transportation to campus. Students will begin the January 2019 semester at the new location, pending final regulatory approval from the U.S. Department of Education.
Prime Minister Mottley, in welcoming Ross University to Barbados, said, “This is the type of investment that is very important to the advancement of the Barbadian economy, and which will also add immeasurably to our diversity. I am confident that this prestigious university campus will impact significantly on the Barbadian landscape on many levels. We are committed to transforming Barbados into a hub for educational and medical services, including educational and medical tourism. We recognise that these areas of tourism are among the fastest growing areas in travel and tourism worldwide. This venture will be an important pillar in that mission. We are very proud of our infrastructure and expect RUSM students and faculty to settle very quickly within our community, benefitting not only academically but also from the rich cultural experiences that they will have while living here.”
Founded in 1978, RUSM is a significant contributor to the U.S. medical workforce. RUSM’s 14,000 diverse alumni practice medicine throughout North America and across all specialties, including a high percentage of graduates who enter the in-demand field of primary care. In September of 2017, Dominica was severely damaged by Hurricane Maria, causing devastation to the island, its buildings and infrastructure, and leading to the safe evacuation of our students and faculty. Since that time, the institution has maintained the quality and continuity of its medical education program at temporary locations while damage assessment, repair and rebuilding has occurred on the Dominica campus.Adtalem is very mindful of the people of Dominica and the needs of the community, and is creating a plan in close coordination with Prime Minister Roosevelt Skerrit and the government of Dominica that will take these matters into meaningful consideration, including an appropriate transition of our campus property and buildings. Furthermore, Adtalem is committed to providing support to colleagues during the transition.

Posted in Estero/world news, Università/University | Contrassegnato da tag: , , | Leave a Comment »

Global Personalized Medicine Scientific and Commercial Aspects Research Report 2018

Posted by fidest press agency su sabato, 21 luglio 2018

This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics, pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results.There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important. The concept of personalized medicine described in this report remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare. Finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2016-2026.Profiles of 332 companies involved in developing technologies for personalized medicines, along with 610 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report. The report is supplemented by 88 tables and 42 figures.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SetPoint Medical Reports Positive Long-term Results from its Clinical Study of Bioelectronic Medicine to Treat Rheumatoid Arthritis

Posted by fidest press agency su venerdì, 22 giugno 2018

SetPoint Medical, a clinical-stage biomedical technology company developing bioelectronic therapy for chronic inflammatory diseases, announced positive long-term data for its first-in-human study using bioelectronic medicine for rheumatoid arthritis (RA). Building on the positive 3-month results that were published in Proceedings of the National Academy of Sciences (PNAS) in 2016, the follow-up through 24 months demonstrated significant, sustained improvement in clinical disease activity scores and disability indices on bioelectronic therapy. The results were presented in a poster session at the Annual European Congress of Rheumatology (EULAR).
Rheumatoid arthritis is a chronic inflammatory disease that affects 1.5 million people in the United States and costs tens of billions of dollars annually to treat. SetPoint is developing a novel bioelectronic medicine platform that stimulates the inflammatory reflex with digital doses of electricity to produce a systemic anti-inflammatory effect.
In this European study, 17 subjects with moderate to severe RA symptoms were implanted with a vagus nerve stimulating device. Early results demonstrated that bioelectronic therapy significantly reduced rheumatoid arthritis symptoms and inhibited cytokine production at three months. Following completion of primary study timepoint, participants had the option of continuing in the follow-up study, and all chose to continue their treatment.All 17 subjects remained on therapy for 24 months. At the 24-month time point, 87% of the subjects reported had clinically meaningful responses by standard EULAR criteria, demonstrating that bioelectronic medicine has the potential to substantially reduce both clinical RA disease activity and patient disability for two years, with no unexpected safety issues. These improvements were maintained in patients with and without concurrent use of biologic agents.“Long-term clinical efficacy is important in the development of cost-effective therapy, and we are pleased to report long-term durability of bioelectronic medicine in RA, with safe and efficacious results that have been maintained for two years,” said Anthony Arnold, Chief Executive Officer of SetPoint Medical.
SetPoint recently initiated a pilot trial evaluating the company’s proprietary device for treatment of drug-refractory RA patients in the U.S.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SanBio: Update on Development Progress of Regenerative Cell Medicine SB623

Posted by fidest press agency su mercoledì, 4 aprile 2018

The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio Inc.) (TOKYO:4592) has updated part of its March 13, 2018 release “Update on Development Progress of Regenerative Cell Medicine SB623”. Updated sections are underlined below.In the SB623 development program targeting chronic motor deficit from ischemic stroke, a Phase 2b clinical trial jointly conducted with Sumitomo Dainippon Pharma Co., Ltd., is under way in the U.S., and enrollment of all 163 patients was completed in December 2017. The results of the trial are due in July 2019 following a 12-month follow-up period. In Japan, on February 14, 2018, SanBio and Teijin Limited terminated their licensing agreement, which previously had out-licensed to Teijin development and marketing of SB623 for stroke in Japan. Concurrently, SanBio initiated its own SB623 development program for chronic deficit from ischemic stroke in Japan with the objective to deliver a product in Japan earlier than in any other market in the world.
In a separate global development program targeting chronic motor deficit from traumatic brain injury (TBI), which SanBio is developing independently in Japan and the U.S., a Phase 2 clinical trial is under way, and patient enrollment has been completed with 61 patients enrolled versus the target of 52 patients. After a six-month follow-up period, SanBio plans to utilize the conditional and time-limited marketing authorization system for regenerative medicine products under the Revised Pharmaceutical Affairs Act of Japan to begin sales for its TBI indication before its other SB623 development programs. Specifically, SanBio plans to publish clinical trial results for its Phase 2 TBI study by the end of the fiscal year ending January 2019 and file for approval in the fiscal year ending January 2020.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

President of the New York State Psychiatric Association Joins Ross University School of Medicine as Chair of Psychiatry

Posted by fidest press agency su mercoledì, 7 febbraio 2018

Seeth VivekSeeth Vivek, MD, DLFAPA, has joined Ross University School of Medicine (RUSM) as Associate Professor and Chair of Psychiatry. Dr. Vivek’s nearly 40-year career has included a number of leadership roles in New York state, where he currently serves as the president of the New York State Psychiatric Association and Chairman of the Departments of Psychiatry and Addiction Services at Jamaica and Flushing Hospitals in Queens, New York. He is also the past president of the Queens County Psychiatric Society.Dr. Vivek will draw upon his experience in mental health advocacy and organized medicine to help RUSM students gain a better understanding of mental health issues and addiction medicine.“Dr. Vivek has been a leader in the field of psychiatry as a clinician, educator and an administrator. With his 360 degree view of medicine, he offers unique insight that will help us enhance our clinical training in psychiatry at our affiliate U.S. teaching hospitals throughout the country,” says Dr. Vijay Rajput, Associate Dean of Clinical Sciences at RUSM. “As students are exposed to Dr. Vivek’s passion for psychiatry and benefit from his extensive experience, students will gain a better understanding of career opportunities in the field and how to establish a path to achieve their aspirations.”“I spent a significant part of my career encouraging colleagues to escape the trap of offering ‘one size fits all’ treatments for their patients. A diagnosis should include all elements and a treatment plan should be comprehensive,” says Dr. Vivek. “I look forward to challenging RUSM students at this stage in their journey about how they think about mental health and treatment for patients.”
Dr. Vivek has been deeply devoted to training the next generation of physicians. He has served as an examiner for the American Board of Psychiatry and Neurology. As a beloved teacher, Dr. Vivek was awarded the Leo Davidoff Award for Excellence in Medical Student Teaching. Other awards Dr. Vivek has received include the Red Cross Award for Distinguished Service following the events of September 11, the Harvey Bluestone Award for Distinguished Service and many other accolades to recognize his public service.Dr. Vivek is board certified in general psychiatry, psychosomatic medicine, addiction psychiatry, forensic psychiatry, geriatric psychiatry and addiction medicine. (photo: Seeth Vivek)

Posted in Università/University | Contrassegnato da tag: , , | Leave a Comment »

American University of the Caribbean School of Medicine Resumes Classes in Sint Maarten following Temporary Relocation after Hurricane Irma

Posted by fidest press agency su venerdì, 19 gennaio 2018

RainbowFour months after Hurricane Irma caused American University of the Caribbean School of Medicine (AUC) to evacuate students and faculty from Sint Maarten, AUC has resumed classes on its Sint Maarten campus. The medical school has begun a phased return to Sint Maarten after holding its September 2017 semester on the campus of the University of Central Lancashire (UCLan) in Preston, United Kingdom.
“The last four months have required a tremendous amount of teamwork, support, and resilience from our students, faculty, and colleagues as well as from UCLan, which welcomed AUC and provided immense support,” said Heidi Chumley, MD, Executive Dean of AUC. “Now we are excited to be back in our campus home, engaging with our community partners in Sint Maarten, and looking forward to playing our part in advancing the country’s continued recovery.”The category 5 hurricane, which swept over Sint Maarten on September 6, 2017, had a major impact on the island, where AUC’s students complete their first two years of medical school. After evacuating more than 700 students, faculty, family members, and staff to the U.S., AUC and its parent organization, Adtalem Global Education, commenced planning to find a temporary site in which to continue classes. Faculty and students mobilized to the UK quickly in September and completed the semester in the first week of January. Now, as Sint Maarten continues to recover and rebuild, AUC is pleased to return for the January 2018 semester. While first, second, and third semester students will be based in Sint Maarten, fourth and fifth semester students will continue their studies in the UK, taught by AUC faculty. These students will benefit from clinical learning opportunities at our affiliated hospital sites in the UK.Throughout the semester, AUC students and colleagues will mobilize to help the country rebuild. In February, the medical school will host Community Action Day, a day dedicated to volunteer work throughout the island. Students will also continue their work on public health, health education, and other programs to benefit the people of Sint Maarten. (photo: Rainbow)

Posted in Estero/world news, Medicina/Medicine/Health/Science, Università/University | Contrassegnato da tag: , , , | Leave a Comment »

Cerevance Appoints David H. Margolin, MD, PhD as Senior Vice President of Clinical and Translational Medicine

Posted by fidest press agency su mercoledì, 29 novembre 2017

Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has appointed David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine. Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications, spanning biologics, small molecules and cell and gene therapies. Notably, Dr. Margolin served as the medical lead for the development of Lemtrada (alemtuzumab) which is now marketed in over 60 countries.A board-certified neurologist with additional expertise in cell and molecular immunology, Dr. Margolin obtained his bachelor’s degree from Harvard College magna cum laude and his M.D. and Ph.D. degrees from the University of Pennsylvania. He completed his residency at Massachusetts General Hospital, followed by a research fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Margolin served on the faculty in neurology at Harvard Medical School for 15 years, has authored more than 30 publications in peer-reviewed journals including The Lancet, New England Journal of Medicine, Brain, Blood, and Neurology, and is an inventor on several patents.“David brings a critical combination of skills to Cerevance, with a stellar track record leading clinical development as well as a deep knowledge of neuroscience,” noted Brad Margus, CEO of Cerevance. “He will ensure the thoughtful execution of our more advanced programs while concurrently helping us dive into our rich human brain tissue datasets to select new drug targets with which we can expand our pipeline.” “Cerevance’s unique platform provides an opportunity to identify novel targets for neurological and psychiatric diseases on an unprecedented scale,” said Dr. Margolin. “I look forward to joining Cerevance’s team, advisors and investors in pursuing their vision of creating innovative and highly effective treatments for the millions of people with these diseases.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Octapharma Donates 30.5 Million International Units of Its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries

Posted by fidest press agency su venerdì, 24 novembre 2017

HaemophiliaOctapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with Project SHARE, North Andover, Massachusetts (USA).Up to 75% of the world’s estimated 400,000 people with haemophilia have little or no access to treatment that resolves life- and limb-threatening bleeds, and enables surgery and rehabilitation. A humanitarian program, Project SHARE facilitates the donation of blood-clotting factor products for the treatment of people with haemophilia in need of factor replacement therapy in countries where these medicines are scarce or still unavailable.Over the last nine months, donations of Nuwiq® have been reaching seriously ill people in need in 16 countries: Armenia, Bahamas, Bangladesh, Barbados, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Honduras, Myanmar, Nepal, Nicaragua, Philippines, Romania and Venezuela.“We are deeply grateful to Octapharma for allowing us the privilege to serve those with haemophilia in developing countries who have limited or no access to treatment. These donations are saving lives,” said Laureen A. Kelley, the founder of Project SHARE.
“Octapharma has been committed to improving the lives of people with Haemophilia A since 1983. We are glad to continue our donation initiatives, providing access to patients with haemophilia in countries with little to no access to therapy,” remarked Olaf Walter, Board Member at Octapharma AG in Lachen, Switzerland.“The haemophilia factor concentrates are used on patients suffering from serious joint and musculoskeletal complications and life-threatening bleeds,” said Walter Mwanda, Patron of the Kenya Haemophilia Association. “Assistance to one you do not know is great, and to a child is even greater. The Kenyans, mainly children living with haemophilia, thank you very much.”“We cannot thank Octapharma and Project SHARE enough to for being so kind and generous,” said Suraksha Mani, of the Nepal Haemophilia Society. “We had limited factor stock when we received the Nuwiq® delivery. People in rural areas now have better access to factor concentrate. We believe this donation has already made positive changes in the lives of many people with haemophilia in Nepal. It has been life-saving and is helping to prevent disabilities.” “This donation of Nuwiq® will help families with haemophilia in Honduras,” said Maria del Carmen of the Honduran Haemophilia Society. “The use of this medicine will serve families because their children and young people will have factor doses in their homes and therefore not miss classes in their schools and universities.” Antonia Luque, Venezuelan Association for Haemophilia, added “We are currently going through a crisis for which we do not have the medicines that people need. There are currently 2185 people living with haemophilia A in Venezuela. Please accept our gratitude for such a valuable donation that will come to relieve cases of our population who are suffering from haemophilia A.” (photo: Haemophilia)

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

ESC on eHealth Revolution: A New Vision For Cardiovascular Medicine

Posted by fidest press agency su venerdì, 24 febbraio 2017

Sophia AntipolisSophia Antipolis. How are smartphones and computer programs transforming healthcare, especially when it comes to preventing, diagnosing and treating heart disease? That’s the focus of a collection of articles published today in the European Heart Journal (EHJ).
Called eHealth, it includes smartphone applications that can predict a patient’s worsening heart failure simply from the sound of a person’s voice, or an app that warns someone walking down a street that blood pressure or glucose levels are dangerously low. There are mobile apps for doctors in the clinic that provide computerised decision support systems.There’s even Big Data that analyses millions of patient records to understand what cardiovascular treatments are having the greatest impact in specific situations, or how the results from one country compare to the results in others.
“Our profession and its use of electronic information is changing rapidly” said Professor Jeroen Bax, president of the European Society of Cardiology (ESC). “Cutting-edge technologies are providing medical insights like never before.”The ESC has representatives working with the European Commission’s Expert groups on eHealth to ensure the interests of cardiovascular professionals and their patients are well represented. The ESC sees eHealth as vital to achieving its mission of reducing the burden of cardiovascular disease and allowing people to live longer, healthier lives.
Professor Martin Cowie, professor of cardiology at the National Health and Lung Institute at Imperial College London, and coordinator of the ESC eHealth Unit, said remote access and personal monitoring would enable heart patients to gather their own data.“eHealth is truly a revolution for health and healthcare. It’s one of the most exciting changes we have seen in decades. It can help empower a person living with a medical condition,” said Professor Cowie. “People don’t have to go to hospital to receive input. They can collect information at home or even when they are out and about pursuing their daily activities and those data can help doctors make better and more timely decisions with them.”
On Big Data, IBM created the cutting-edge technology platform Watson that can help a physician diagnose a medical complaint by combing through more than a million textbooks and scientific abstracts within seconds. “We are a catalyst to translate big data to empower doctors so they can take more time with their patients,” said Dr. Kyu Rhee, chief health officer at IBM.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Milano: Master internazionale in Pharmaceutical Medicine

Posted by fidest press agency su domenica, 18 dicembre 2016

università studi milanoMilano Grazie alla collaborazione tra Novartis e Università degli Studi di Milano nasce il Master internazionale in Pharmaceutical Medicine – presentatoa Milano – che propone una formazione avanzata, basata sul dialogo tra accademia, ricerca di base e industria farmaceutica, nella consapevolezza comune che la collaborazione è vitale per tutti gli attori e che, come le migliori esperienze internazionali dimostrano, contribuisce a rendere il sistema più dinamico e competitivo.Gli studenti, selezionati in questi giorni da un bando internazionale, saranno calati da subito direttamente nella realtà della ricerca. Le lezioni teoriche si terranno, infatti, presso il Centro Daccò dell’Istituto Mario Negri, che rappresenta un esempio unico di struttura in grado di accogliere e sviluppare tutte le fasi di un progetto di ricerca clinica e dove professionalità diverse (medici, infermieri, biologi, farmacologi, bioingegneri, tecnici di laboratorio, esperti di statistica, informatici) lavorano in stretta collaborazione per valutare lo stato di salute del paziente, raccogliere i dati degli studi e rielaborarli al fine di determinare l’efficacia di nuove strategie terapeutiche.Fase fondamentale della caratterizzazione del nuovo Master è il tirocinio, che sarà svolto presso la sede di Novartis, struttura d’eccellenza della ricerca e sviluppo di nuovi farmaci, che conferma con il sostegno a questa iniziativa il proprio impegno a valorizzare i giovani talenti delle bioscienze e a promuovere nuovi modelli imprenditoriali grazie alla sinergia tra accademia, industria, non profit, istituzioni e investitori.
Il master inizierà il 31 marzo 2017 e avrà una durata di 12 mesi, corrispondente a 1500 ore, e si articolerà tra lezioni frontali, attività di gruppo e tirocinio. Per gli studenti più meritevoli saranno rese disponibili 3 borse di studio, a totale copertura dei costi.Attraverso questa iniziativa i giovani laureati hanno l’opportunità di comprendere e sperimentare concretamente come le competenze scientifiche si possono tradurre in soluzioni di elevato valore economico e sociale, coniugando le esigenze della pratica clinica alle finalità industriali. Nell’ambito del Master, grande rilevanza viene data anche alla preparazione sulle procedure e le dinamiche dell’interazione tra accademia, industria e autorità regolatorie durante le diverse fasi di sviluppo del farmaco.Commenta Gianluca Vago, Rettore dell’Università Statale di Milano: “E’ significativo che questo Master nasca a Milano e in Lombardia, realtà che si è affermata come hub farmaceutico europeo e che si sta sempre più caratterizzando a livello internazionale come punto di riferimento per le nuove terapie mediche avanzate. Questa iniziativa rafforza il profilo fortemente orientato all’innovazione del nostro territorio e conferma l’impegno della Statale a creare sinergie in grado di sostenere con progetti come questo l’offerta di un approccio diagnostico e terapeutico all’avanguardia, che trasformi il meglio della ricerca scientifica in aiuto di cura per chi è malato.”“Oggi le frontiere della medicina delineano nuove straordinarie sfide, alle quali il mondo della ricerca e sviluppo farmacologico è chiamato a dare risposta”, sottolinea Guido Guidi, Head of Pharma Region Europe, Novartis. “Ci troviamo di fronte a un cambio epocale di paradigma, nel quale novità come la medicina di precisione e le Advanced Medical Therapies impongono una riformulazione di tutto il percorso della terapia: dalla ricerca di base allo sviluppo in tutte le sue fasi, fino all’utilizzo nelle cure. E, di conseguenza, anche i criteri relativi ad accesso, regolamentazione e pricing & reimbursement devono essere radicalmente rivisti. Per dare risposta a queste richieste, Novartis crede fermamente nella necessità di creare anche nuovi percorsi rivolti ai giovani laureati, per metterli in condizione di acquisire le competenze necessarie per ridisegnare la medicina del futuro”. “Il Master integra in un unico curriculum tutti gli aspetti e le competenze coinvolti nel processo di ricerca e sviluppo di un nuovo farmaco, abbattendo le barriere tra ricerca di base, applicata e quella industriale”, aggiunge Giuseppe Remuzzi, ordinario di Nefrologia alla Statale, coordinatore delle Ricerche all’Istituto Mario Negri di Bergamo e coordinatore del Master. “Diamo ai nostri studenti la possibilità di un percorso formativo basato sull’acquisizione di un forte background scientifico, un approccio alla ricerca rigoroso e critico, l’esperienza pratica e la conoscenza della realtà dell’industria, tutti passaggi essenziali per il successo dello sviluppo di nuove terapie”.

Posted in Cronaca/News, Medicina/Medicine/Health/Science, Università/University | Contrassegnato da tag: , , , | Leave a Comment »